Package Leaflet: Information for the User
Meropenem Aurovit 500 mg powder for solution for injection and infusionEFG
Read all of this leaflet carefully before you start using this medicine because it contains important information for you.
Contents of the pack
Meropenem Aurovit contains the active substance meropenem and belongs to a group of medicines called carbapenem antibiotics. It works by killing bacteria that can cause serious infections.
Antibiotics are used to treat bacterial infections and do not work for viral infections such as flu or the common cold.
It is important to follow the instructions regarding the dose, administration interval, and treatment duration indicated by your doctor.
Do not store or reuse this medicine. If you have any leftover antibiotic after finishing the treatment, return it to the pharmacy for proper disposal. Do not throw away medicines via wastewater or household waste.
Meropenem is used to treat the following infections in adults and children from 3 months of age:
Meropenem can be used to treat patients with neutropenia who have fever that is suspected to be due to a bacterial infection.
Meropenem can be used to treat bacterial infection of the blood that may be associated with one of the aforementioned types of infection.
Do not use Meropenem Aurovit
Warnings and precautions
Consult your doctor or pharmacist before starting to use Meropenem Aurovit:
Liver problems
Tell your doctor if you notice yellowing of the skin and eyes, itching of the skin, dark-colored urine, or light-colored stools. This may be a sign of liver problems that your doctor should check.
You may develop a positive reaction to a test (Coombs test) that indicates the presence of antibodies that can destroy red blood cells. Your doctor will discuss this with you.
You may develop signs and symptoms of severe skin reactions (see section 4). If this happens, inform your doctor or nurse immediately so that they can treat the symptoms.
If you are in any of these situations, or if you have doubts, consult your doctor before using meropenem.
Other medicines and Meropenem Aurovit
Tell your doctor or pharmacist if you are taking, have recently taken, or might take any other medicines.
This is because meropenem can affect the way some medicines work, and some of these may have an effect on meropenem.
In particular, tell your doctor or nurse if you are taking any of the following medicines:
Pregnancy and breastfeeding
If you are pregnant or breastfeeding, think you may be pregnant, or are planning to have a baby, ask your doctor or pharmacist for advice before using this medicine. It is preferable to avoid the use of meropenem during pregnancy. Your doctor will decide whether you should use meropenem.
It is important that you inform your doctor if you are breastfeeding or plan to breastfeed before receiving meropenem. Small amounts of this medicine pass into breast milk. Therefore, your doctor will decide whether you should use meropenem during breastfeeding.
Driving and using machines
No studies on the effects on the ability to drive and use machines have been performed. However, meropenem has been associated with headache; tingling or numbness in the skin (paresthesia); and involuntary muscle movements, leading to rapid and uncontrolled body movements (convulsions), which are usually accompanied by loss of consciousness. Any of these effects could affect your ability to drive or use machines.
Meropenem Aurovit contains sodium
This medicine contains approximately 45 mg of sodium (main component of table salt/cooking salt) per vial.
The maximum recommended daily dose of this medicine contains 540 mg of sodium. This is equivalent to 27% of the maximum recommended daily intake of sodium for an adult.
Consult your doctor or pharmacist if you need 8 or more vials per day for a prolonged period, especially if you have been recommended a low-salt (sodium) diet.
Follow the instructions for administration of this medicine exactly as indicated by your doctor or pharmacist. If in doubt, consult your doctor or pharmacist again.
Adults
Use in children and adolescents
The dose for children over 3 months and up to 12 years is determined using the child's age and weight. The normal dose is between 10 mg and 40 mg of meropenem per kilogram (kg) of the child's weight. A dose is usually given every 8 hours. Children who weigh more than 50 kg will be given an adult dose.
If you use more Meropenem Aurovit than you should
If you accidentally use more than the prescribed dose, contact your doctor or go to the nearest hospital immediately.
In case of overdose or accidental ingestion, consult your doctor or pharmacist immediately or call the Toxicology Information Service, phone 91 562 04 20, indicating the medicine and the amount ingested.
If you forget to use Meropenem Aurovit
If you forget an injection, you should receive it as soon as possible. However, if it is almost time for the next injection, do not receive the missed one.
Do not use a double dose (two injections at the same time) to make up for a missed dose.
If you stop using Meropenem Aurovit
Do not stop Meropenem until your doctor tells you to.
If you have any further questions on the use of this product, ask your doctor, pharmacist, or nurse.
Like all medicines, this medicine can cause side effects, although not everybody gets them.
Severe allergic reactions
If you have a severe allergic reaction, stop using meropenem and go to a doctor immediately. You may need urgent medical treatment. The symptoms can include:
Damage to red blood cells (unknown frequency)
The symptoms include:
If you notice any of the above, go to a doctor immediately.
Other possible side effects:
Common(may affect up to 1 in 10 people)
Uncommon(may affect up to 1 in 100 people)
Rare(may affect up to 1 in 1,000 people)
Reporting of side effects
If you experience any side effects, talk to your doctor, pharmacist, or nurse. This includes any possible side effects not listed in this leaflet. You can also report side effects directly through the Spanish Pharmacovigilance System for Human Use Medicines: www.notificaram.es. By reporting side effects, you can help provide more information on the safety of this medicine.
Keep this medicine out of the sight and reach of children.
Do not use this medicine after the expiry date which is stated on the carton after EXP. The expiry date refers to the last day of the month shown.
No special storage conditions are required.
Injection:
After reconstitution: The reconstituted solutions for intravenous injection should be used immediately. The time between the start of reconstitution and the end of intravenous injection should not exceed:
Infusion:
After reconstitution: The reconstituted solutions for intravenous infusion should be used immediately. The time between the start of reconstitution and the end of intravenous infusion should not exceed:
From a microbiological point of view, unless the method of opening/reconstitution/dilution rules out the risk of microbiological contamination, the product should be used immediately.
If not used immediately, the storage times and conditions are the responsibility of the user.
Do not freeze the reconstituted solution.
Medicines should not be disposed of via wastewater or household waste. Ask your pharmacist how to dispose of medicines no longer required. This will help protect the environment.
Composition of Meropenem Aurovit
Each vial contains meropenem trihydrate equivalent to 500 mg of anhydrous meropenem.
The other component is anhydrous sodium carbonate.
Appearance of the Product and Container Content
Meropenem Aurovit is presented in the form of powder for injectable solution and for infusion.
It must be dissolved before use and administered directly by injection or infusion.
The medication is presented in glass vials containing a white or slightly yellow powder, in packages with 1 vial or 10 vials.
Marketing Authorization Holder and Manufacturer
Marketing Authorization Holder
Eugia Pharma (Malta) Limited
Vault 14, Level 2, Valletta Waterfront
Floriana, FRN 1914
Malta
Manufacturer:
ACS Dobfar S.p.A.
Nucleo Industriale S. Atto, S. Nicolò a Tordino
64100 Teramo
Italy
You can request more information about this medication by contacting the local representative of the marketing authorization holder:
Aurovitas Spain, S.A.U.
Avda. de Burgos, 16-D
28036 Madrid
Spain
This medication is authorized in the Member States of the European Economic Area under the following names:
Germany: | Meropenem Inresa |
Spain: | Meropenem Aurovit 500 mg powder for injectable solution and infusion EFG |
Poland: | Meropenem Zentiva |
Portugal: | Meropenem Color |
Romania: | Meropenem Zentiva |
Date of the last revision of this prospectus: September 2025
This information is intended only for healthcare professionals:
Instructions for administering Meropenem Aurovit to yourself or another person at home
Some patients, parents, and caregivers are trained to administer meropenem at home.
Warning – You should only administer this medication to yourself or another person at home after a doctor or nurse has trained you.
How to prepare this medication
Dose of Meropenem Aurovit | Amount of "Water for Injection" needed for dilution |
500 mg (milligrams) | 10 ml (milliliters) |
1 g (gram) | 20 ml |
1.5 g | 30 ml |
2 g | 40 ml |
Note that:If the amount of Meropenem Aurovit prescribed for you is greater than 1g, you will need to use more than one Meropenem Aurovit vial. You can then draw up the liquid from the vials into a syringe.
Administration of the Injection
You can administer this medication through a peripheral intravenous catheter or through a central port or line.
Administration of Meropenem Aurovit through a Peripheral Intravenous Catheter
Administration of Meropenem Aurovit through a Central Port or Line